OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, November 16, 2010

Updated Oct 2010: Genetic Syndromes - Genetics of Breast and Ovarian Cancer - National Cancer Institute



Major Genes

Introduction


BRCA1
BRCA2
BRCA1 and BRCA2 Function


Mutations in BRCA1 and BRCA2
Variants of uncertain significance


Prevalence and Founder Effects


Models for Prediction of the Likelihood of a BRCA1 or BRCA2 Mutation


Penetrance of Mutations
Cancer risk in individuals who test negative for a known familial BRCA1/2 mutation
Breast and ovarian cancer risk in breast cancer families without detectable BRCA1/2 mutations


Population Estimates of the Likelihood of Having a BRCA1 or BRCA2 Mutation


Role of BRCA1 and BRCA2 in Sporadic Cancer


Genotype-Phenotype Correlations


Pathology/Prognosis of Breast Cancer
BRCA1
BRCA2
Contralateral breast cancer in BRCA mutation carriers

Pathology/Prognosis of Ovarian Cancer
Pathology
Prognosis

Other Rare Breast and Ovarian Cancer-Associated Syndromes
Li-Fraumeni syndrome
Cowden syndrome
Peutz-Jeghers syndrome

Families and Scientists Gather to Discuss Research and Treatment for Li-Fraumeni Syndrome



An archived video of the full meeting is available through the NIH Videocast Web site.

"...Li-Fraumeni syndrome was first described in a 1969 publication in the Annals of Internal Medicine by Dr. Joseph F. Fraumeni, Jr., the director of DCEG, and his colleague Dr. Frederick P. Li. They described four families in which several members developed a wide variety of cancers as children or young adults. Many of the patients had multiple primary tumors, most notably breast cancer, soft tissue and bone sarcomas, brain tumors, adrenocortical neoplasms, and acute leukemia. Subsequent studies identified additional families that met the classic criteria for LFS. Other families had similar but less pronounced aggregations of cancer and were classified as Li-Fraumeni-like (LFL)...."

(OVA1 ovarian cancer blood test) Vermillion Inks New Agreement with Quest Diagnostics - GLG News




Firm prepares for cancer patents hearing - The New Lawyer (BRCA patents) - Australia




Canary Foundation of Canada




Canary Foundation - Ovarian Cancer Program



Figure 1: Stage at Diagnosis Figure 2: Survival by Stage of Diagnosis

Expansion of cancer care and control in countries of low and middle income: a call to action : The Lancet



Note: includes a number of easy to read charts/comparisons

Editorial: Cancer: the revolution has begun : The Lancet




BRCA | prIME Oncology conference notice Tel Aviv, Israel Nov 18-19th




Advancing Ethical Research Conference - December 2010





abstract + Free Full-Text (2010) Familial Pancreatic Cancer (includes discussion regarding BRCA/Lynch Syndrome/FAMMM and others)



Abstract: Pancreatic cancer’s high mortality rate equates closely with its incidence, thereby showing the need for development of biomarkers of its increased risk and a better understanding of its genetics, so that high-risk patients can be better targeted for screening and early potential lifesaving diagnosis. Its phenotypic and genotypic heterogeneity is extensive and requires careful scrutiny of its pattern of cancer associations, such as malignant melanoma associated with pancreatic cancer, in the familial atypical multiple mole melanoma syndrome, due to the CDKN2A germline mutation. This review is designed to depict several of the hereditary pancreatic cancer syndromes with particular attention given to the clinical application of this knowledge into improved control of pancreatic cancer.
Keywords: phenotypic and genotypic heterogeneity; high mortality; genetic counseling; biomarker paucity; FAMMM syndrome; Li-Fraumeni syndrome; Lynch syndrome; pancreatic cancer

Management of Unexplained Symptoms in Survivors of Cancer — JOP abstract



M.R.I.’s Help Women at High Risk for Breast Cancer - NYTimes.com



Monday, November 15, 2010

press release: Australia - "FTY720" New treatment to overpower drug resistance in ovarian cancer



"Recent studies have also shown anti-tumour efficacy in several types of cancers but this is the first time it has been studied for the treatment of ovarian cancer."

New Therapies for Neuroendocrine Tumors (carcinoid tumors)



Note: Medscape requires (free) registration to view

Session Overviews Pharma-Nutrition 2011 Conference Netherlands conference notice/program



UK versus US health care: Atlantic rift : Editorial The Lancet



"Sadly, the political rancour about who spends what and on whom diverts attention from the real key to tackling chronic disease, and the only thing with the power to save both lives and money—disease prevention."

Women's Health in Asia | The Lancet Conferences Dec 2-5th announcement



a collection of videos: Ovarian Cancer - Cancer Health (including Ovarian Cancer and Our Pets - minus audio)



New test for ovarian cancer patients - RAD51 assay (UK)



Note: search blog for additional RAD51 information/studies

Margaret Polaneczky, MD - HRT Worries – This Time, It’s Ovarian Cancer Again…. | The Blog That Ate Manhattan (see simple charts)




Ovarian cancer drug shows promise with move to phase 3 trial (AMG 386) Clinical Oncological Society of Australia




Search of: ovarian cancer | Open Studies - List Results - ClinicalTrials.gov



Found 528 studies with search of: ovarian cancer | Open Studies

WORD on Cancer Team



Sunday, November 14, 2010

Abstract/full free access: Risk factors for perioperative venous thromboembolism (blood clots) : A retrospective study in Japanese women with gynecologic diseases




Surgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approach.



CONCLUSIONS: Previous studies document survival benefit of surgery for women with recurrent ovarian cancer when there has been a long disease-free interval, localized pelvic or intra-abdominal recurrences and an optimal performance status. Most gynecologic oncologists do not perform extensive liver or diaphragm resections or lymph node excision above the renal vessels; thus, collaboration with a surgical oncologist is a viable option. In this small descriptive study, the feasibility of this reasonably well-tolerated approach, with possible survival benefit, is documented.

Does the time interval between first and last birth influence the risk of endometrial and ovarian cancer?



CONCLUSION: Our findings suggest that the risk of endometrial cancer is significantly decreased for women having at least a difference of 10 years between their first and last birth. Ovarian cancer does not seem to be influenced by the time interval between first and last birth.

2011 full free access: Cancer Biology & Therapy Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer




Antiproliferation effect of commercially brewed coffees on human ovarian cancer cells in vitro




The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer



Abstract

AIM: The objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer.
CONCLUSION: This study has demonstrated that the systematic lymphadenectomy had benefit only in patients with ovarian cancer macroscopically confined to the pelvis. In patients with clear cell adenocarcinoma, systematic lymphadenectomy was beneficial. To the contrary, systematic lymphadenectomy had no benefit on OS or PFS in patients with advanced ovarian cancer if optimally debulked.

full free access: Extraordinarily Prolonged Disease Recurrence in a Granulosa Cell Tumor Patient



Background
Granulosa cell tumors are rare sex cord stromal lesions that comprise approximately 3% of all ovarian neoplasms. The vast majority of granulosa cell tumors are considered indolent but in spite of aggressive management, delayed recurrence is of significant concern.
Conclusion
Granulosa cell tumors are considered to be of low malignant potential but they have the capacity to recur, even several years following initial patient management. This case exemplifies the disease's capacity for prolonged recurrence and further accentuates the significance of long-term follow-up in these patients.

Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor (negative study)




The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not effect progression-free or overal survival



Abstract

BACKGROUND.: Studies have suggested that erythropoietin-stimulating agents (ESAs) may effect progression-free survival (PFS) and overall survival (OS) in a variety of cancer types.

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer



BACKGROUND: Sequential treatment with azacitidine can induce re-expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Systemic chemotherapy--before (neoadjuvant) or after radical surgery in treatment of patients with advanced ovarian carcinoma?




Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary (case report)



Definition: Brenner tumours are uncommon tumours that are part of the surface epithelial-stromal tumour group of ovarian neoplasms

Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer.




Impact of platinum-based chemotherapy on the progression of atherosclerosis



Definition: Atherosclerosis (also known as arteriosclerotic vascular disease or ASVD) is the condition in which an artery wall thickens as the result of a build-up of fatty materials such as cholesterol

Abstract/full free access: Population-based study of ovarian cancer in Cote d'Or (France): prognostic factors and trends in relative survival rates over the last 20 years




Consumption of dietary fat and meat and risk of ovarian cancer - the American Journal of Clinical Nutrition



Design: The NLCS includes 62,573 postmenopausal women, aged 55–69 y at baseline, who completed a baseline questionnaire on dietary habits and other risk factors for cancer in 1986. After 16.3 y of follow-up, 340 ovarian cancer cases and 2161 subcohort members were available for a case-cohort analysis. Multivariable rate ratios (RRs) were adjusted for age at baseline, total energy intake, oral contraceptive use, and parity

[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.



Abstract

AIM: The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses......

Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.




Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting.




abstract: Opening the psychological black box in genetic couseling - impact uninformative result



Psychooncology. 2010 Nov 11. [Epub ahead of print]

Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.

 

 

Book Review - The Emperor of All Maladies - A Biography of Cancer - By Siddhartha Mukherjee - NYTimes.com




Tuesday, October 19, 2010

Comments | Decisions at the end of life: have we come of age? full free access - open for commentary





Decisions at the end of life: have we come of age?

Linda Emanuel email and Karen Glasser Scandrett email
BMC Medicine 2010, 8:57doi:10.1186/1741-7015-8-57


Blog addressing educational, research and genetics needs in ovarian cancer/related populations

(Commentary) Sandi Pniauskas (19 October 2010) Ovarian Cancer and Us email
Congratulations to the authors for addressing the issue of changing values and needs of patients at the close of life. Most North American studies on this topic err in their original suppositions regarding the preferred place of death. Generally the focus has been institutional and cost based as opposed to the values and ethics of yes, human dignity in dying. Specific to the needs of oncology patients/families, it is often disturbing to view reports asking citizens where they wish to die when we should know and understand that this answer cannot be of any value until those patients and families are 'in the moment'. The moment-to-moment changes in physical and emotional changes in cancer patients/families and all of the psycho-physio changes require that our systems adapt. Numerous real life examples of institutional/provider interference in the wishes of the dying are disturbingly unconscionable. The question which needs to be addressed is: 'Who's on 'first'?" Having witnessed circumstances where best practices were not followed in favour of cost analyses, we have to ask ourselves who will say no to money before suffering?
Competing interests
ovarian cancer survivor, Lynch Syndrome

Wednesday, October 13, 2010

Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna re: Survivors' Debate (Ovarian Cancer) - repost



Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna

by Dr. Hsien-Hsien Lei
Posted September 28, 2007 in DNA Testing, DNA and Disease, Personalities with DNA

How times have changed. Cancer has come from being taboo to being a subject of debate. Even better, ever more cancer survivors are now leading the charge for better healthcare.
Two ovarian cancer survivors, Sandi Pniauskas and Carolyn Benivegna, have joined to hold the Survivors Debate: The Past Decade in Ovarian Research. Two events are scheduled for October 27 in Michigan and November 3 in Toronto. Details are available at the Survivors Debate blog.
Earlier this week, Sandi and Carolyn participated in an exclusive interview with me for Eye on DNA. Learn more about what it’s like to have ovarian cancer and these women’s experiences with genetic testing. Their very personal stories remind us of the realities of cancer.
~~~~~
Hsien Lei: What is it like to have ovarian cancer as opposed to other forms of cancer?
carolynCarolyn Benivegna: Naturally, some forms of cancer are worse than others in terms of prognosis. I have no doubt that ovarian cancer will eventually kill me. I’m a fighter, though, and I keep beating it back with the biggest sticks I can find. I have been doing this for over nine years, though they said I probably wouldn’t live two years at the time of my diagnosis. Having ovarian cancer causes me to be angry at “the system” sometimes because ovarian cancer does not get its fair share of research funding or educational/awareness efforts. This has improved over the past decade, but it’s got a long way to go.
sandiSandi Pniauskas: This is an interesting question and indeed one which is very difficult to explain. I believe that most cancer patients/family caregivers might feel the same way at the time of the initial cancer diagnosis, so I will try to explain. I think the word ‘Cancer’ is first heard and then secondarily the type of cancer. As we know from public opinion polls, the vast majority of people do not necessarily understand that cancer is not a singular disease, but many different types and each one has its own set of treatments, prognosis and profile. People often ask what type of cancer, but after that, due to the lack of awareness and education, the detailed information does not ’stick’. Improvements in this area are being made, but it is my opinion, that we must change tactics because what we have been doing is not working for the vast majority.
I knew what ovaries were of course, but, had no idea that there was a cancer called ovarian cancer. Ovaries are indeed what makes women – women and this seems like such a rather insignificant statement . That is until we realize that not having ovaries (due to surgical intervention) makes a huge impact on the way we see ourselves, as women, not to speak of the complications which result and in particular premenopausal women, such as myself, due to surgical intervention. Similar to other cancers, it is not a cancer that you can ’see’, but not having ovaries, again, is not only biologically complex but emotionally as well. I guess I might try to equate this with cancer of the gall bladder. Trying to put this into context, as an example, may be gall bladder cancer patients and this is said with the greatest of respect for those patients. Patients, cancer or not, can live without a gall bladder but it is not typically associated with an extreme physical or emotional dysfunction.
With ovarian cancer comes the surprise that you don’t need to visit ‘that’ particular aisle of the drug store anymore. It’s a small issue in the larger picture, but part of every woman’s life. In fact, I think it took me 6 months to realize that the trek down this pharma aisle was no longer required. It’s a fact, which still to this day, strikes me with a small amount of humour. The larger less humourous issue is the lack of the ability to have children and while a select few ovarian cancers are spared, this is not the norm.
As to the broader question of other forms of cancer, I would have to say that now, when the words of ovarian cancer are mentioned, it brings a reaction of “Oh, that’s a bad one’” but on the other hand, often times, the general public believe that you take out the ovaries and get on with your life, along with maybe a little chemo. It is a sense of dismissal that is concerning and that indeed exists within our patient populations to some degree today. This is very concerning and very unfortunate.
Hsien: Sandi, you had a significant history of cancer in your family. How did that influence your approach to finding treatment for your own cancer?
Sandi: In fact, the realization came only after the fact in our situation. So, allow me to explain because it is important and sends a key message for the benefit of others.
When I was first diagnosed, and as the eldest of 5 siblings, I said I was ‘happy’ for the ovarian cancer diagnosis. Why ‘happy’? I thought, in a very uninformed way, that this meant that through my diagnosis I was ‘it’ for the family – that I had taken the ‘cancer hit’ for the family and so the others would be spared. In fact, 6 months and 1 year later two younger sisters also had cancer diagnoses. We were all in our ’40’s and 3 cancer diagnoses in a time span of 2 years, a fact which is quite stunning.
Since this time, I have come to realize that not only are we not alone, but indeed, there are worse families with many more incidents/deaths of cancers. After the diagnosis of cancer of the 3rd sibling, it dawned on me that something was not right. I remembered my Mother talking about her Grandmother and ‘being in bed all of the time because she was sick from cancer”. I pursued obtaining the medical death certificate for my Great-Grandmother and indeed, she died of colo-rectal and endometrial (uterine) cancers. My Grandfather also died of a cancer but I was unable to locate that information.
As with other families, there was no one still alive to ask for further information and this made it more challenging, but not insurmountable. The unfortunate part of all of this, in hindsight, is that it did not have to happen but it wasn’t necessarily the fault of anyone person, just the set of circumstances and timing. Unlike our situation, however, if there is any cancer diagnosis in the family it would be important to explore the family history right at the time of the initial diagnosis rather than letting it happen, so to speak. It might have saved my younger sister from her death, not to mention the suffering.
We are part of the genetic syndrome which is called the Lynch Syndrome and sometimes it is known as the ‘family cancer’ because of the wide range of cancers experienced in these families, ovarian cancer of which is one. Since I had already had my treatments, approach to treatment is an after-the-fact question. However, I had encouraged my younger sister to maintain a heightened surveillance program as her risk factors were the most similar to mine. At the time and before her diagnosis, I did not understand the connection and the risk for other cancers.
Would a heightened awareness and surveillance program have influenced her outcome? The answer at the very least is quite possibly.

teal ribbonHsien: Carolyn, do you also have a family history of cancer? How did this knowledge affect you?
Carolyn: Yes, my maternal grandmother died of breast cancer, my maternal grandfather died of stomach cancer, and my maternal aunt died of ovarian cancer. There was also some breast cancer on my father’s side of the family (two of his sisters). That’s why I was always conscientious about breast cancer screening, never dreaming that I was a candidate for ovarian cancer (having had my ovaries removed many years before my ovca diagnosis). After I was dx. with ovca, I insisted on genetic testing and was found to be BRCA-1 positive. Since then 12 other members of my family have been tested for that specific genetic mutation, and they are ALL positive.
The knowledge of the genetic mutation affected me by moving me into action to educate my family members about the genetic predisposition to the various cancers in the BRCA-1 mutation. It has also influenced my decisions on which treatments to take.
Hsien: How did you feel before, during, and after genetic testing (prior to receiving your results)?
Carolyn: I think I was generally numb before my genetic testing. I knew I had to do it, and I did it. I had been diagnosed, had surgery, and had two of six scheduled chemo treatments when I decided on genetic testing.
When I was found to be BRCA-1 positive, I was disappointed because it meant that my children were at risk due to something I had inadvertently passed on to them. Though I know I shouldn’t feel guilty about this, I can’t help feeling responsible for passing on something to them that could cause them a lot of pain and illness sometime in the future.
I’m glad I was tested, however, because I believe that knowledge gives us the power to make enlightened decisions about our healthcare. Prior to my diagnosis, I was not knowledgeable about ovarian cancer or genetic mutations and, consequently, was diagnosed at Stage IIIC Primary Peritoneal Cancer.
Sandi: I initiated the genetic testing for both the BRCA 1/2 and the Lynch Syndrome after our diagnoses. The rationale for the BRCA testing was due to unknown cancer types in our family, as well as a female first cousin, who was diagnosed with an early-age breast cancer. At this point, for me, the question was not what, but what to do with the information.
From a strictly scientific perspective and to bring research forward, I knew that genetic testing might one day bring a resolution to many of the unanswered questions and for the benefit of our future generations. So, I tried to look at this very clinically. Because I pursued the genetic testing after completing my treatments of surgery, chemotherapy and radiation, I had the benefit of time to reflect on the emotional issues. I often times try to convey to people that if we can, and it is not always possible, we need to put that emotional aspect in ‘a little box’. This is what I was able to do and this is strictly an individual response.
Not having had children also was of benefit because there was no burden of passing along those genes, which in my own personal set of circumstances made the genetic testing a much easier decision. If I had had children, the decision would have become much more complicated.
At the initial time of pursuing the genetic testing, I didn’t believe that waiting for the test results would be an issue. Understanding that while genetic testing in Canada is covered under our universal healthcare system, the results are not received in a timely manner. The results of the BRCA testing took 4 months and the results of the Lynch Syndrome testing took approximately a year. I kept myself very busy with ovarian cancer advocacy issues and participation in our international online community which is an easy way to say, I kept myself busy. However, not long after, I told the genetic counselor that while I thought waiting for the test results was not an issue, indeed, it was.
The BRCA results were negative which I anticipated. The Lynch Syndrome testing was ‘inconclusive’ meaning they were unable to locate anyone of the known genes. It is my belief that the only truly significant result is a positive result and while this stuns many people, to me a positive result means that there is some form of certainty and as a result there is a plan of action. An inconclusive result does not answer the question. Having said this, without a conclusive result, meaning a positive result, we are still faced with the reality of the family history and are waiting for science to catch up with us.
I do have to say that I am very encourage by new and recent research findings and while this does not necessarily, depending on the genetic syndrome, at this time, translate into day-to-day care, it will. After receiving the results, I am a firm advocate for awareness both within the healthcare professional communities and patient communities for the benefit of those who might be at risk for any familial link/cancer predisposition through a known genetic syndrome. It is important also for all cancer patients to understand that there are quite a number of different syndromes, so appropriate genetic counselling is crucial.
Hsien: After receiving the results of your genetic tests, how did you feel? How did the results influence your life choices?
Sandi: At this time, there are few options available for my future life choices. Surveillance and screening are available for only 2 of the cancers for which I am at risk. Fortunately, the highest risk for me at this point is colo-rectal cancer and there is screening available through colonoscopies. For those other cancers of which I am risk, there is no screening. However, we have taken care of endometrial and ovarian cancer risks due to my onset of ovarian cancer. While I am at a lesser risk for stomach and pancreatic cancers, I am hoping that those are not the ones which I will die from. At the same time, there continues to be the risk of a late/new ovarian cancer although small. Risk is all relative and risk is only low if it is not you – that’s the mind-game in all honesty.
Hsien: What do you think will be the hottest topics of the Survivors Debate? You specifically mention genetics and access to care and communications. How do your two viewpoints differ from one another? What do you hope people will do after attending the Debate?
Carolyn: I think one of the hottest topics will be “Access to Care.” This is a big issue in the U.S. right now and is a problem here and throughout the world. Sandi and I actually agree on many subjects. For the sake of the debate, we are taking opposing viewpoints on all the issues so that we can present diametrically opposite viewpoints, as a debate should!
I (personally) hope the debate will help create an environment where survivors will be included more in the dialog and decision-making processes as they pertain to cancer. I hope the controversy spurred by the debates will accelerate forums of this nature, resulting in increased research, treatment, and communication that includes survivors as the very core.
Sandi: One of the most important features of the Survivors’ Debate programs is that it allows, without bias or judgment, a public forum for people to express themselves through dialogue and indeed challenge the issues of what is not working. We know what is working, but we need to address what is not – publicly.
Personally, I am tired of doing the same-old, same-old. What always worries me is that many patients feel that by speaking up and out that this will impact their care. We must and need to change this sense of, in some cases a lack of entitlement, and it take a great deal of morale fortitude to do so. We encourage healthcare providers to attend en masse and also speak openly about their own issues. We want you to sit side by side with your patients – the human compassion and understanding which we will all take away with us will be the greatest and most successful and lasting result. It is also hoped that with public debate we can apply pressure for change. I have the belief and know that we can, but the question is will we?
There is a lot of anger amongst all of us, most of which is related to system failures. Today, we still have not been able to address the issues of the Patients voices in any effective way. Patients for the most part have the highest regard for their professional caregivers and want to have these dialogues. Fear of the unknown holds us back but it is decidedly less of a fear than the cancer itself, in my view. At the moment, other people are speaking for cancer patients and their families and we are at the point where the information is not being translated effectively.
The dichotomies in the medical literature attest to this where patients/family caregivers and medical staff do not have the same opinions on what is important. In fact, many healthcare professionals’ stories also note these issues. This is not so much of a criticism but a recognition of where we need to go. It is my profound expectation and hope that through these public forums we can bridge this gap. The debate forums allow us to take that much needed step forward, translating patients intellect and sense of responsibility and bring with it a public voice as opposed to a non-cancer voices in healthcare decision-making. If we do not do this, changes will occur which will not be effective in any meaningful way to those for whom we serve – the patients. This in fact, will be the change and from my perspective of mutual benefit to all.
On a personal level, I have lost not only family but most of the friends whom I first came into contact with when newly diagnosed. I simply cannot accept the degree of suffering which I experience each day, through others, without at least trying to take yes, a controversial but important step forward. These forums are not without controversy but we must put aside the issues which consistently get in the way of moving forward. I cannot think of a better or more humane way in which to do so.
Carolyn and I agree, as Carolyn mentions, on most issues. Most importantly ovarian cancer is a global issue and while some of the access to care are points of technical issues, the reality is that ovarian cancer to Carolyn and ovarian cancer to me, are the same. We both think this is extremely exciting that today patients are or can be the experts in their own cancers. If by chance, our information is lacking, then we want to know and we cannot underestimate how we truly believe this. An oncologist once told me that a little information is a dangerous thing. After initially being significantly annoyed, I decided he/she was right. These are our efforts to profile and dialogue what is not understood about the ‘average’ cancer patient but more important what is important. The learning curve has been steep, but it can be done.
The Debates are the mechanism to do so.
Thank you so much for allowing us to present our views, concerns and hopes for the future.
~~~~~
Bravo, Carolyn and Sandi! Thank you for sharing your stories and thoughts with us. There are many cancer survivors who will undoubtedly be inspired by your proactive determination.

Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna re: Survivors' Debate (Ovarian Cancer) - repost




Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna - Ovarian Cancer Survivors' Debate (repost)



Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna

Monday, October 11, 2010

ESMO - ICON 7 - Avastin Shows Promise For Ovarian Cancer Treatment



Further evidence that Avastin improved progression free survival in women with ovarian cancer was presented by researchers at the European Society of Medical Oncology (ESMO) congress in Milan, Italy. A new Phase III Avastin (ICON7) trial showed again that women with chemotherapy-naïve ovarian cancer had better progression free survival compared to women only on chemotherapy. A chemotherapy-naïve patient is one who has never received chemotherapy.

ICON7 is the second Phase III clinical trial on Avastin for ovarian cancer treatment. It compared chemotherapy-naïve women on Avastin plus chemotherapy versus similar patients on just chemotherapy. PFS (progression free survival) was approximately 27% better among those in the Avastin group; this corresponded to a 21% drop in the chances of cancer progression to death, the investigators explained. GOG0218, the first Phase III pivotal Avastin trial, had demonstrated earlier this year that Avastin plus chemotherapy and then alone gave ovarian cancer patients a 54% higher chance of progression free survival compared to women on chemotherapy alone.The Avastin dosage was smaller in the ICON7 trial, which also lasted less time....cont'd

full free access: A review and characterization of the various perceptions of quality cancer care - Jnl Cancer



"...Patient Perspectives

Thirteen studies reported patient perceptions of quality cancer care from >9000 patients (Table 1). Five of those 13 studies enrolled exclusively patients with breast cancer (N = 1039), whereas 1 study enrolled only patients with colorectal cancer (N = 1067). Four studies included 6905 patients with any cancer or with 1 of several kinds of cancer.

When information was difficult to obtain, trust was limited, or care was not well coordinated, patients experienced reduced quality of care.
 
Patient characteristics associated with unfavorable perceptions of care quality
Three studies identified patient and clinical characteristics that were associated with unfavorable perceptions of quality care. These characteristics included factors related to health status, type of treatment, living conditions, and sociodemographic characteristics of the patients, including age, income level, ethnicity, and language spoken (Table 3)....."

Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival



Blogger's Note: discussions/research have been made in the past regarding triple therapies (irrespective of types of therapies) with most resulting, if not all, leading to increased toxicities/no survival advantage

"...Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.

Cisplatin plus paclitaxel, and carboplatin plus paclitaxel, are the most widely accepted first-line regimens for advanced epithelial ovarian cancer. Still, most women relapse and die from their disease. One possible solution is to add a third agent, such as topotecan, which has activity in the treatment of recurrent disease. However, combining topotecan with carboplatin plus paclitaxel as a triplet therapy is problematic because of bone marrow toxicity. So, to integrate topotecan into the standard regimen researchers tested cisplatin plus topotecan followed by carboplatin plus paclitaxel.

The phase III randomized study included 819 women aged 28-78 with newly-diagnosed stage IIB or more advanced ovarian cancer. The study was led by Paul Hoskins, M.D., of the British Columbia Cancer Agency in Vancouver and colleagues from three other groups: the NCIC Clinical Trials Group at Queen's University in Kingston, Canada, the European Organization for Research and Treatment of Cancer – Gynecologic Cancer Group, European Union, and the Grupo EspaÅ„ol de Investigación en Cáncer de Ovario in Spain.

The women in the study were from Canada and Europe, and were randomly assigned to one of two study groups: the first arm received cisplatin and topotecan, followed by carboplatin and paclitaxel; the second arm received only carboplatin and paclitaxel...."

A Do-It-Yourself Genomic Challenge to Myriad, the FDA and the Future of Genetic Tests (long)



PARP Inhibitor Adds Nearly 5 Months to Breast Cancer Survival (BRCA/discussions) : Internal Medicine News



Physical symptoms prevalent no matter what stage of cancer including remission



"....The study of 405 patients was reported in the Oct. 11, 2010, issue of the Archives of Internal Medicine. Numerous physical symptoms, rather than just a few, were prevalent in patients with cancer and this prevalence did not diminish after completion of therapy. "We found that regardless of where they are in the course of their diseases, many individuals with cancer have a high symptom burden," said Kurt Kroenke, M.D...."cont'd

abstract/full free access: Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units



Abstract:

Systematic reviews of randomized trials that include measurements of health-related quality of life potentially provide critical information for patient and clinicians facing challenging health care decisions. When, as is most often the case, individual randomized trials use different measurement instruments for the same construct (such as physical or emotional function), authors typically report differences between intervention and control in standard deviation units (so-called "standardized mean difference" or "effect size"). This approach has statistical limitations (it is influenced by the heterogeneity of the population) and is non-intuitive for decision makers. We suggest an alternative approach: reporting results in minimal important difference units (the smallest difference patients experience as important). This approach provides a potential solution to both the statistical and interpretational problems of existing methods.


Sunday, October 10, 2010

The Oncologist: Peer-Reviewed Supplement: Assessing and Improving Value in Cancer Care Oncology in the Trenches



Table of Contents

How Should We Define Value in Cancer Care? Listen to the Audio Podcast

Scott Ramsey, M.D., Ph.D., Adam Schickedanz,

Beyond Costs and Benefits: Understanding How Patients Make Health Care Decisions
Peter A. Ubel, M.D.

Therapy for Advanced Stage Cancer: What Do Patients Want and Expect? A Patient Advocate's Perspective
Robert L. Erwin, M.S.

The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology
Amy E. McKee, M.D.

What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?
Daniel Sargent, Ph.D.

Drug Pricing and Value in Oncology
Patricia M. Danzon, Ph.D ., Erin Taylor

The Responsibility to Pay for Cancer Treatments: A Health Insurer's View of Value
Lee N. Newcomer, M.D.

Ethical and Value Issues in Insurance Coverage for Cancer Treatment
Dan W. Brock, Ph.D.

Ethical Issues in Patient–Physician Communication About Therapy for Cancer: Professional Responsibilities of the Oncologist
Neil S. Wenger, Paul M. Vespa

Rewarding Value Creation to Promote Innovation in Oncology: The Importance of Considering the Global Product Life Cycle
Louis P. Garrison, Jr., Ph.D.

Uncertainty in Assessing Value of Oncology Treatments
C. Daniel Mullins, Russ Montgomery, Sean Tunis, M.D.

Concrete Options and Ideas for Increasing Value in Oncology Care: The View from One Trench
Thomas J. Smith, M.D, Bruce E. Hillner

Of Value: A Discussion of Cost, Communication, and Evidence to Improve Cancer Care
Adam Schickedanz


Audio Podcasts/full free access paper - The Oncologist Community - How Should We Define Value in Cancer Care?



http://theoncologistcommunity.com/multi-media/audio-podcasts.html


(audio) How Should We Define Value in Cancer Care?

Description: This paper aims to construct a definition of value in cancer care and to argue for the application of that definition in our evaluation of care for cancer

(text - full free access):
  http://theoncologist.alphamedpress.org/cgi/content/full/15/suppl_1/1

Patient Advisory Committee: ECCO PAC/eurocancercoms Roundtable -



"A roundtable of ECCO's patient advisory committee was convened at this year's ESMO conference in Milan to discuss the impact and utilisation of new media to provide cancer information to patients and their families."

Avastin - ESMO: Blocking Angiogenesis Slows Ovarian Cancer - in Meeting Coverage, ESMO from MedPage Today




free full access: Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review




abstract: Clinical features of 215 stage I ovarian tumors in Japanese women (borderline vs stage 1 clear cell; stage1C)



PURPOSE: Differences of the clinical features of Stage I borderline ovarian tumors and Stage I ovarian cancer need to be clarified.
METHODS: We retrospectively investigated 215 patients with Stage I ovarian tumors (67 with borderline tumors and 148 with ovarian cancer) treated between 1988 and 2001.
RESULTS: Only one patient with a borderline tumor developed recurrence, while recurrence was found in 20 patients with Stage I ovarian cancer. There was a significant difference in the recurrence rate between patients with Stage Ia or Ib ovarian cancer and those with Stage Ic cancer (p = 0.007). Clear cell adenocarcinoma showed a higher recurrence rate. Among our patients with recurrence, only five in whom the recurrent tumor could be surgically resected are currently alive and disease-free.
CONCLUSIONS: This study confirmed the low aggressiveness of Stage I borderline ovarian tumors and high aggressiveness of Stage Ic ovarian cancer or clear cell adenocarcinoma. In patients with recurrence, surgical resection may improve survival.
PMID: 20882880 [PubMed - in process]

abstract: Recall of intensive care unit stay in patients managed with a sedation protocol or a sedation protocol with daily sedative interruption



CONCLUSION: A notable percentage of patients discharged from the ICU report moderate to extreme pain, anxiety, and fear, and inability to sleep during their ICU stay; and 29% to 48% have no recall of specific ICU events.

Avoiding Syndrome of Inappropriate Antidiuretic Hormone Secretion in Dying Patients



Note: good article discussing sensitive issues especially important for understanding by patients/families

"Palliative care physicians know that they should not overhydrate terminally ill patients, but many do not understand why. We have provided the physiologic reasons."

recruiting: Clinical Outcomes in Hereditary Cancer - Full Text View - ClinicalTrials.gov BRCA/pancreatic/breast



Purpose

Compare the clinical characteristics and post-surgical outcomes (overall survival)of pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 .

Compare the clinical characteristics and outcomes (time to progression) of breast cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 receiving paclitaxel chemotherapy for metastatic disease.

Prize for journalist who tackled taboo subject of rationing cancer therapies Cancer World



short video: commentary Dr Maurie Markman - Neoadjuvant Chemotherapy for Advanced Ovarian Cancer



8th Symposium on Advanced Ovarian Cancer 2011 (Spain) - GEICO - ESMO - European Society for Medical Oncology



It is a great honor and privilege for us to present you this 8th International Symposium on Advanced Ovarian Cancer: Optimal Therapy. Update, organized since 2009 in partnership between the Spanish Ovarian Cancer Research Group (GEICO) and the European Society for Medical Oncology.

This comprehensive multidisciplinary symposium covers all of the hot and innovative topics surrounding the diagnosis, biology, and therapy of ovarian cancer. In fact our meeting has grown to be recognized internationally as a classical educational event, offering a platform for many of you to gather, to teach, to learn, and also to discuss both the value and the methodology of how standard, as well as new approaches are being incorporated into the management of ovarian cancer.

More than 350 participants from all over the world attended the last edition of the meeting in 2009. It will be a pleasure to welcome all of you on 4th March 2011 in Valencia. Please reserve the date today!

On behalf of the Organizing Committee,

Andrés Poveda & Jan B Vermorken
Symposium Directors

For further information, please visit: www.doctaforum.com/aocsymp

Patient Seminar 2010 - ESMO - European Society for Medical Oncology Oct 9th/10th



8th ESMO Patient Seminar

ESMO is pleased to announce that the 8th Patient Seminar will be held during the 35th ESMO Congress, Milan 2010.

The 8th ESMO Patient Seminar will be held at the Congress venue of the 35th ESMO Congress, the Fiera Milano Congressi, Milan, Italy.

The Seminar, dedicated to cancer patients, family members, representatives of cancer leagues and patient groups, will open on Saturday afternoon, 9 October, with welcome speeches and keynote lectures, followed by a full day of sessions on Sunday, 10 October 2010. The Seminar will cover a wide range of subjects, with the aim of encouraging direct interaction and communication between oncology patients and healthcare professionals.

The lectures will be given in English and Italian.

Saturday, October 09, 2010

Happy Thanksgiving Canada!



abstract: Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure — JCO




Purpose Area under the curve (AUC) dosing is routinely carried out for carboplatin, but the chosen target AUC values remain largely empirical. This multicenter pharmacokinetic-pharmacodynamic (PK-PD) study was performed to determine the covariates involved in the interindividual variability of carboplatin hematotoxicity that should be considered when choosing individual target AUCs. 

Patients and Methods Three hundred eighty-three patients received carboplatin as part of established regimens. A semi-physiologic population PK-PD model was applied to describe separately the time course of absolute neutrophil and platelet counts using NONMEM software. The plasma ultrafiltrable carboplatin concentration (CCarbo) was assumed to inhibit the proliferation of blood cell precursors through a linear model: drug effect = slope × CCarbo. The slope corresponds to the patients' sensitivity to carboplatin hematotoxicity. The relationships between the patients' sensitivity to the neutropenic or thrombopenic effects of carboplatin and various covariates, including associated chemotherapies, demographic, biologic, and pharmacogenetic data, were studied. 

Results The sensitivity of carboplatin-induced thrombocytopenia decreased in the case of concomitant paclitaxel chemotherapy (slope decreased by 24%), whereas it increased with coadministration of etoposide and gemcitabine (slope increased by 45% and 133%, respectively). For neutropenia, the sensitivity increased when carboplatin was combined with other cytotoxics (slope increased by 76%). 

Conclusion This study provides useful information to clinicians to better estimate the hematopoietic toxicity of carboplatin and thus choose more rationally carboplatin target AUCs as a function of pretreatment or concomitantly administered chemotherapies. For example, an AUC of 5 mg/mL · min is associated with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel versus 38% with gemcitabine in a non-pretreated patient.

World Consumer Health Congress, Washington, DC, Slides thrown away, Conference turned “un” | Ted Eytan, MD



Do We Need a War on Rare Diseases? - Health Blog - WSJ




‘You’ve Got Mail’ — But Not From Your Doctor! Only 7% Are Emailing Patients - Health Blog - WSJ




abstract: Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort




Investigational ovarian cancer drug (MLN8237) shows promise against platinum resistant disease



Phase II trial

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.
Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO).
MLN8237 selectively inhibits an enzyme known as Aurora A kinase, which is a member of a family of kinase enzymes involved in normal cell division. Researchers have found that Aurora A kinase is over-expressed in some cancer cells, leading to growth of cancers.
"In epithelial ovarian cancer, Aurora A kinase has been reported to be frequently upregulated or overexpressed, and associated with worse clinical outcome," Dr Matulonis said. "This is why an effective Aurora A Kinase inhibitor is a potential new therapy to be used alone or in combination with other standard agents such as paclitaxel."...cont'd

abstract: Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression



Background: Evaluation of patients for Lynch syndrome includes assessment of age and family cancer history as well as testing for microsatellite instability and alterations in mismatch repair (MMR) genes. We examined the value of routine immunohistochemistry (IHC) for MMR proteins in patients with colorectal cancer (CRC) undergoing resection at a single institution.
Patients and Methods: Beginning in July 2006, all patients aged < 50 years who were undergoing resection of primary CRC had their specimens routinely examined by IHC for MMR proteins. Patients aged 50-60 years were examined if histopathology suggestive of Lynch syndrome was reported, and patients of any age were examined if strong clinical suspicion was present. Family cancer history was analyzed and fulfillment of Amsterdam II criteria determined.
Results: Over an 18-month period, 96 patients aged < 50 years underwent CRC resection. Out of these, 72 patients (75%) had immunohistochemical testing, with an overall MMR protein loss rate of 19%. In selected patients aged 50-60 years and > 60 years, loss rates were 26% and 65%, respectively. Of all patients with MMR protein loss, 10 (32%) had reported histopathology, and 3 (10%) had family histories suggesting Lynch syndrome.
Conclusion: We demonstrate the feasibility of routine immunohistochemical testing for MMR proteins in patients with CRC. As only a minority of patients with MMR protein loss met Amsterdam II criteria or had suggestive histopathology reported, routine IHC may identify patients with Lynch syndrome who might otherwise be missed.

Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent... PRNewswire/ --



Oct. 9 /PRNewswire/ -- Amgen today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The updated results, now including data on overall survival, are being presented in a poster discussion at the 35th European Society for Medical Oncology (ESMO) Congress being held in Milan, Italy. (Abstract Number: 975PD)...."cont'd

The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy - Markman (very short abstract)



abstract: "It is rational to suggest that the decision to alter treatment in advanced ovarian cancer should be based on the totality of evidence that the disease is worsening, on patient tolerability of the therapy, and on a determination that the current regimen is providing no benefit or unacceptably limited benefit to the specific individual. Knowledge of an objective measure of “progression” should play an important, but not a singular, role."

U.S. FDA: About the Center for Drug Evaluation and Research > Carboplatin dosing



Carboplatin dosing

"This communication is to inform members of the oncology community of recent changes in the measurement of serum creatinine which may have an impact on carboplatin dosing. Based on preliminary communications with the National Cancer Institute/Cancer Therapy Evaluation Program, a potential safety issue with carboplatin dosing has been identified. By the end of 2010, all clinical laboratories in the US will use the new standardized Isotope Dilution Mass Spectrometry (IDMS) method to measure serum creatinine. The IDMS method appears to underestimate serum creatinine values compared to older methods when the serum creatinine values are relatively low (e.g., ~0.7 mg/dL). Measurement of serum creatinine by the IDMS-method could result in an overestimation of the Glomerular Filtration Rate (GFR) in some patients with normal renal function. If the total carboplatin dose is calculated based on IDMS-measured serum creatinine using the Calvert formula, carboplatin dosing could be higher than desired and could result in increased drug-related toxicity...."cont'd

Friday, October 08, 2010

Malinda Teel: Clinical Trials from the Patient's Perspective | Ovarian Cancer National Alliance




Practice-Changing Results to Be Presented at ESMO - Medscape Medical News from the: * 35th European Society for Medical Oncology (ESMO) Congress



October 8, 2010 (Milan, Italy) — A record number of abstracts were submitted and accepted, and a record number of attendees expected, here at the 35th European Society for Medical Oncology Congress. In addition, findings from major phase 3 trials may change clinical practice in lung, breast, ovarian, and prostate cancer.....

CANHELP Tool - questionnaires/tools/end of life care - patients, caregivers, bereavement, healthcare providers



View the questionnaire measuring SATISFACTION only:
Documents (pdf):

* CANHELP Patient Questionnaire
* CANHELP Caregiver Questionnaire
* CANHELP Bereavement Questionnaire

View the Questionnaire measuring IMPORTANCE and SATISFACTION:

* CANHELP Patient Questionnaire
* CANHELP Caregiver Questionnaire

Canadian Health Reference Guide-Patients and caregivers want more support at the end of life



New tool helps patients and families communicate their needs

'NanoKnife' - HealthNewsReview.org Reviews of News Stories | Holding Health and Medical Journalism Accountable



free full access: Health care providers (doctors and nurses) underestimate symptom intensities of cancer patients



Note: plain english format (easy to read) "The differences between patient and provider assessments can be caused by providers not being able to exactly interpret the patients' symptoms or that different instruments are used for patients and health care providers. Agreement on rating of symptoms was associated with demographic- and disease-related factors. Clinicians involved in care for patients with cancer should be aware of the potential factors associated with a risk of symptom underestimation."

Thursday, October 07, 2010

prior abstract - new commentary: EvidenceUpdates - Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment



Commentary:
Oncology - Gynecology - "This negative study extends the evidence base indicating that triplet chemotherapy increases toxicity without significant survival benefit in ovarian cancer patients. Further increases in survival for this group will need to come from alternate strategies."

alternate link to abstract:
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer

abstract: “When patients and families feel abandoned”



Conclusions

These strategies can help us maintain healing relationships with our patients by maintaining their trust, confidence, and satisfaction. Cultivating relational aspects of medical practice requires an interchange and takes time. Experienced doctors know this and continue to do so because being present and staying with the patient during difficult times is a pillar of moral and ethical training and a fundamental attribute of a good physician.

Can a Facebook status do anything to fight cancer? - The Globe and Mail (plus commentaries)




Correspondence/Response: Patient Information and Decision Aids in Oncology: Need for Communication Between Patients and Physicians — JCO



1):    
Correspondence (Vodermark):
"In their recent contribution to Journal of Clinical Oncology, Brace et al1 report on the knowledge and opinions of physicians caring for patients with cancer in the province of Ontario, Canada, about patient decision aids......Brace et al1 must be congratulated for collecting this comprehensive data set on the oncologists' perspective on this important topic. However, it is possible that the rates of decision aid use by patients may actually be higher than suggested by the percentages for physicians responding to the questionnaire. Access to disease-specific patient decision aids is provided freely on the Internet, and patients may make use of these tools without discussing them with their treating oncologists..."cont'd

2):


Response to Vodermark (Erin D. Kennedy)
We appreciate the comments by Vordermark1 about our recent contribution to Journal of Clinical Oncology.2
"...We agree that the Internet certainly has the potential to be an excellent and accessible information resource for both patients and physicians. The results presented by Vordermark et al3 and Adler et al4 are both interesting and timely, given that these data suggest that patients seeking information on the Internet are not comfortable discussing the information with their physicians. This is similar to our own group's experience in which patients seem to be increasingly more confident in the information they find on the Internet rather than in their own physicians. This is somewhat concerning, and we must begin to question whether we as physicians are slowly losing the ability to connect with our patients.......To accomplish this, researchers need to involve (not avoid) physicians in both the development and implementation of pDAs and decision support tools. " 



Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study — JCO



Note: abstract does not indicate if ovarian cancer patients were included in this phase 1 study

abstract: Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve — JCO



Note: ages of participants

Women's Health Matters Network: Women's College Hospital (Toronto) patient survey (n=1,000)



 Some background:
The new facility will include the Women’s College Research Institute (WCRI), making women’s health research a key focus.

‘Our research institute is one of the few in the world – and the only one in Canada – devoted to women’s health and innovations in ambulatory care,’ said Dr. Lorraine Lipscombe, an endocrinologist at Women’s College Hospital and a scientist at the WCRI who spoke at the event.

‘Our scientists ask questions that are not only unique to women’s lives, but that are specific to distinct communities of women.’



Selected results:
"Some notable results:

* Only 30 per cent of respondents said they felt empowered when dealing with health-care providers. A great many women had less positive feelings: 45 per cent said they felt isolated when visiting a hospital, 57 per cent said they felt afraid, 63 per cent felt frustrated and 76 per cent felt anxious.

* Sixty-five per cent of women felt they were treated like a number rather than a person, and 70 per cent felt the focus was on rushing them through their appointments and treatments rather than discussing their needs and circumstances.

* The vast majority – 88 per cent of respondents – said it was essential to approach health care holistically, treating the whole person rather than isolated body parts. However, less than half that number (43 per cent) felt that hospitals and health-care facilities actually achieved this.

* Most women prefer to remain in the community – and in their lives – while their conditions are treated. Ambulatory care – or outpatient treatment, as opposed to being admitted to hospital – was the preference of 90 per cent of respondents.

* A health-care facility that is knowledgeable about, sensitive to, and actively addresses diverse cultures was important to 80 per cent of respondents.

* More than 85 per cent of women feel women’s health issues should be a research priority for a health-care institution. However, only 56 per cent think institutions successfully keep women’s health at the forefront of research programs."

Wednesday, October 06, 2010

Michelle's (Robinson) MIssion to Educate Hawaii | Ovarian Cancer National Alliance




revamped website: (U.S.) Science Serving People - National Cancer Institute



Cancer Research Progress icon

Cancer Research Progress

Information on research advances and a look at the future of cancer prevention, detection, treatment, and survivorship.
NCI Budget Information icon

NCI Budget Information

National Cancer Institute (NCI) budget requests, data on NCI spending, and an overview of how the institute’s annual budget process works.
Cancer Research in Your Community icon

Cancer Research in Your Community

Clinical trials and NCI collaborations as well as state-specific cancer information.
Understanding Cancer Statistics icon

Understanding Cancer Statistics

Key facts about the human and economic cost of cancer and resources to help make the data more understandable.
How Cancer Research Works icon

How Cancer Research Works

A look at the process of conducting cancer research — from basic science in the laboratory to treatment in the clinic.
Updates and Highlights icon

Policy Highlights

Updates on federal cancer news and congressional testimony.

2010 online AJCC Cancer Staging Manuals (requires subscription $$$)




Help us fight cancer! EU (FACE)



We hope you will join the Forum Against Cancer Europe (FACE) and we call on you to work towards implementing the European Parliament Cancer Resolution by supporting us in our campaign to:

1. Encourage and adopt national Charters for patients' rights according to European guidelines to ensure that the rights of cancer patients are upheld and enforced.
2. Urgently develop and, where existing, improve national cancer plans, setting priorities and effectively allocating resources for improving cancer control and research across the European Union, paying attention to rare or difficult to treat cancers.
3. Ensure cancer patients are included in formulating and monitoring all research, legislation and policies that affect their health.
4. Invest in cancer prevention in Member States and implement the Council Recommendation on Cancer Screening of 2003 by setting up or improving national high quality population-based screening programmes.
5. Vigorously promote cancer awareness in the general public through the existing Europe against Cancer Code.
6. Make timely, high quality and up to date information, diagnosis, treatment and care available for all cancer patients in each European Member State..
7. Firmly tackle the socio-economic and geographic divide, which leads to inequalities in cancer control
8. Oppose discrimination in the latest cancer treatment because of age, race, gender and domicile.

The Forum Against Cancer Europe (300 patient groups/patient-governed)



The "Forum Against Cancer Europe" is an initiative by the European Cancer Patient Coalition (ECPC). ECPC is representing more than 300 cancer patient groups across 42 countries, most in the EU Member States. It is run and governed by cancer survivors, is publicly audited, and is registered as a non-profit association in the Netherlands.

Tuesday, October 05, 2010

NCI Cancer Bulletin - Physician Assistants Valued for Patient Care and Research Support at NCI



financial news: PREVIEW-New cancer data may be tonic for sickly Roche | Reuters



"Frings said Roche would file for European regulatory approval of Avastin in ovarian cancer by the end of the year, with a U.S. submission following in 2011."

Regina Holliday is not special! | e-Patients.net (discussion Gilles Frydman Oct 5th, 2010/ACOR)



Dancing with N.E.D. Trailer on Vimeo - rock star band for ovarian/gyn cancers - gynecologic oncologists



Dancing with N.E.D. Trailer from Spark Media on Vimeo.

Dancing with NED - A Cancer Rock Documentary | Ovarian Cancer National Alliance



<iframe src="http://player.vimeo.com/video/13338331" width="400" height="225" frameborder="0"></iframe><p><a href="http://vimeo.com/13338331">Dancing with N.E.D. Trailer</a> from <a href="http://vimeo.com/user4027907">Spark Media</a> on <a href="http://vimeo.com">Vimeo</a>.</p>This video is a trailer produced by Washington D.C.-based Spark Media and Stone Soup Productions for a documentary about one of the year’s most talked about rock bands, No Evidence of Disease (NED). NED are a group of six GYN surgeons, scattered across the country, who create and perform original music to help raise awareness and research funding for GYN cancers, spread healing through music, and help humanity in general rock out.

(book) Commentary: The politics of precancer : The Lancet



"....The fact that most cases of cancer in this self-defined population (BRCA) was of a non-familial form and that the frequency of the mutation did not translate into a higher rate of cancer was ignored....."


Preventive strikes: women, precancer, and prophylactic surgery  By Ilana Lowy

 

Audio/Video Insights, Implications, Questions, Answers: Report of the Investigators of Surgical and Pathology Issues at Three Essex County Hospitals



Note: this audio/video (62 minutes) refers to the investigation into this year's media reports concerning unnecessary mastectomies/pathology issues and national public exposure of the issue; quality of surgical and pathology care in Windsor/Essex counties (Ontario); notes co-operative investigation (patients??...still listening - terms of reference....)

new stats on Ovarian Cancer and Us blog



This week's stats: most views by country - U.S., France, Canada and UK

Surveillance MRI viable alternative to risk-reducing mastectomy in BRCA mutations | HemOncToday



Life-Saving Developments in Ovarian Cancer Research | Reader's Digest Canada



September – ovarian cancer month – was marked with the usual high-profile events to raise funds and awareness. September 2010, however, will be remembered as particularly significant for this most deadly of women’s cancers.

(repost) Pathways » The Rise of the Empowered Patient




Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations - abstract



CONCLUSION: First-degree relatives of women with very early-onset breast cancer are at increased risk of cancers not explained by BRCA1 and BRCA2 mutations.

Fear of Pain in Patients With Advanced Cancer or in Patients With Chronic Noncancer Pain - abstract




media: U.S. New health care changes are only the beginning - CNN.com



"....Patient advocates say Thursday's changes are only the beginning. "The big resolutions will come in 2014 when you will start to see tens of millions of people getting coverage," says Avram Goldstein, communication director for the Health Care for America Now, a liberal grass roots health advocacy organization. It offers a detailed timeline of what changes consumers can expect over the next few years..." cont'd

Ovarian cancer care for the underserved: Are surgical patterns of care different in a public hospital setting? abstract



CONCLUSIONS:

Ovarian cancer patients treated in public hospitals are less likely to have gynecologic oncologists and high-volume surgeons involved in their care. This is a preliminary finding that warrants further investigation.

OpenNotes Project "levels the playing field" between doctors and patients -- Canadian Medical Association Journal



"....The OpenNotes Project aims to improve communication and transparency between doctors and patients, many of whom don’t even realize notes are being taken, says Dr. Tom Delbanco, a lead investigator of the study. "We share these notes with consultants, insurers and people who evaluate quality of care, but almost never with the patient. I think providers feel these are their own records, rather than their patients’, so in quiet ways, perhaps unconsciously, they build up obstacles to patients gaining access to them." As in Canada, American patients have a legal right to review their doctors’ notes as part of their medical records. However, those who wish to gain access to the files often face prohibitive printing or copying fees, lengthy processes and delays, as well as all manner of bureaucratic red tape, says Delbanco. "At the same time, it’s been shown patients remember very little of what goes on in the examining room."...cont'd

Monday, October 04, 2010

Chemobrain ... Is It Real?



Cancer Newsline - 09/20/2010
Chemobrain, or difficulty in efficiently processing information, is a legitimate, diagnosable condition that may be caused by chemotherapy treatment, the cancer itself, or secondary medical conditions such as anemia. Christina Meyers, Ph.D., Professor of Neuro-Oncology at MD Anderson Cancer Center, discusses chemobrain and how it can affect cancer patients.

Guest(s): 
Christina Meyers, Ph.D.

U.S. webinar Oct 7th - Upcoming Webinar: Pre-Existing Condition Insurance Plans Created by the Affordable Care Act - The Commonwealth Fund



The Commonwealth Fund invites you to join a free webinar on pre-existing condition insurance plans, part of a series of webinars on realizing health reform's potential. This one-hour webinar, to be held Thursday, Oct. 7, at 2 p.m., E.T., will address the Affordable Care Act provision on establishing temporary high-risk pools, also called preexisting condition insurance plans (PCIP), which are designed to quickly make health insurance available to uninsured individuals with preexisting conditions, many of whom previously had been denied coverage. Speakers will examine eligibility, benefits, premiums and cost-sharing, enrollment and outreach, and oversight of the PCIP programs, as well as plan variability.

What: 'Realizing Health Reform's Potential' Webinar: Pre-Existing Condition Insurance Plans Created by the Affordable Care Act

When: Thursday, Oct. 7, at 2 p.m., E.T.

Speakers:
Jean P. Hall, Ph.D., associate research professor at the University of Kansas and author of a new Commonwealth Fund report on PCIPs, and Amie Goldman, CEO, the Health Insurance Risk-Sharing Plan Authority in Wisconsin and chair of the National Association of State Comprehensive Health Insurance Plans; and Deborah Armstrong, executive director, New Mexico Medical Insurance Pool

Moderator: Sara R. Collins. Ph.D., vice president, Affordable Health Insurance, The Commonwealth Fund

To register, go to: https://cc.readytalk.com/r/8ctspn2599j0

Women's Health Highlights: Recent Findings (numerous topics including ovarian cancer)




Herbs and Supplements: special section MedlinePlus




The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer



Conclusions

Although elderly patients appear to tolerate fewer cycles of IP chemotherapy, they do not have higher objective complication rates or impaired PFS compared to younger patients. Age alone should not limit access to IP chemotherapy.

Sunday, October 03, 2010

Incidentally… avoiding the problem of incidental findings (Practical Ethics)



"A new study from the Mayo clinic in the United States points to a frequent           problem in certain types of medical research. When healthy volunteers or patients with a given condition take part in research studies they may have brain scans, CAT scans, blood tests or genetic tests that they wouldn’t otherwise have had. These tests are not done for the benefit of the individual, they are designed to answer a research question. But sometimes, quite often according to the authors of this new study, researchers may spot something on the scan that shouldn’t be there, and that could indicate a previously undiagnosed health condition. These ‘incidental findings’ generate an ethical dilemma for researchers....."cont'd

Perspective Towards a framework for personalized healthcare: lessons learned from the field of rare diseases




Increased risk of other cancers for relatives of women with early onset breast cancer | e! Science News



Published: Wednesday, September 29, 2010 - 18:23 in Health & Medicine
 
Close relatives of women diagnosed with breast cancer before the age of 35 years are at an increased risk of developing other cancers, according to a University of Melbourne study, published in the British Journal of Cancer today. Professor John Hopper, Director of Research from the Centre for Molecular, Environmental, Genetic and Analytic Epidemiology at the University of Melbourne, Australia, a lead investigator in the study, said these are surprising and novel findings which could be pointing to the existence of a new cancer genetic syndrome.
"The results suggest there could possibly be undiscovered genes causing breast cancer in these young women, and perhaps other cancers in their families," Professor Hopper said.
Every year in Australia, more than 300 women are diagnosed with breast cancer before the age of 35 years. This is approximately one in 40 of all breast cancers.
In the largest population based study of its kind, scientists studied 2200 parents and siblings of 500 women diagnosed with breast cancer before the age of 35 from across three countries, Australia, Canada and the United States.
After excluding families with mutations in BRCA1 and BRCA2, the two known major breast cancer susceptibility genes, they found that close relatives were at increased risk of not only breast cancer, but also of cancers of the prostate, lung, brain and urinary tract.

The results showed:
  • Fathers and brothers had a 5-fold increased risk of prostate cancer.
  • Mothers and sisters had a 2-fold increased risk of ovarian cancer as well as a 4-fold increased risk of breast cancer
  • Close relatives also had a 3-fold increased risk for brain cancer, an 8-fold increased risk for lung cancer, and a 4-fold increased risk for urinary tract cancers.
"We wanted to find out what caused the early onset of breast cancer in these women and found some results we weren't expecting regarding their relatives," Professor Hopper said.
"The results of this study could help scientists discover new cancer susceptibility genes that explain the risk of early-onset and other cancers within some families," he said.
"Our next step is to conduct larger studies to further clarify these results."

FDA Alert: Aromatase Inhibitors in Products Marketed as Dietary Supplements: Recall




full free access: New developments in treatment of ovarian carcinoma: focus on Trabectedin



Note: click on 'pdf' for full free access to paper

Medical News: AACR: All Cancer Therapies May Impair Memory - in Oncology/Hematology, Chemotherapy from MedPage Today




abstract: Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics — Clinical Cancer Research



Results:

Fifty-one patients in 43 families were enrolled, with mean age of 52 years, 35% of whom were male. Of these patients, 31 underwent EUS and 33 MRI. EUS revealed two patients with pancreatic cancer (one resectable, one metastatic), five with intraductal papillary mucinous neoplasms (IPMN), seven with cysts, and six with parenchymal changes. Five had pancreatic surgery (one total pancreatectomy for pancreatic cancer, three distal and one central pancreatectomy for pancreatic intraepithelial neoplasia 2 and IPMN).

A total of 24 (47%) had genetic testing (19 for BRCA1/2 mutations, 4 for CDKN2A, 1 for MLH1/MSH2) and 7 were positive for BRCA1/2 mutations. Four extrapancreatic neoplasms were found: two ovarian cancers on prophylactic total abdominal hysterectomy and bilateral salpingo-oophorectomy, one carcinoid, and one papillary thyroid carcinoma. Overall, 6 (12%) of the 51 patients had neoplastic lesions in the pancreas and 9 (18%) had neoplasms in any location. All were on the initial round of screening. All patients remain alive and without complications of screening.